Arcellx experienced a significant increase in net loss in the first quarter of 2025, reaching -$62.27 million, compared to -$7.198 million in the same period last year. This was primarily due to a substantial decrease in collaboration revenue and a rise in research and development expenses.

Arcellx reported a net loss of $47.1 million for Q4 2024, with collaboration revenue decreasing to $15.3 million. The company ended the quarter with $625.7 million in cash, cash equivalents, and marketable securities, projecting a cash runway into 2027. Key clinical highlights include positive preliminary data from the iMMagine-1 study for anito-cel, showing high overall response rates and a manageable safety profile.

Arcellx reported collaboration revenue of $26.0 million for the third quarter of 2024, an increase of $11.0 million compared to the same period in 2023. The company's cash, cash equivalents, and marketable securities totaled $676.7 million as of September 30, 2024, which is expected to fund operations into 2027. Net losses for the quarter were $25.9 million.

Arcellx reported a $68 million milestone payment from Kite for iMMagine-1 enrollment and the FDA cleared anito-cel IND application for myasthenia gravis. Cash, cash equivalents, and marketable securities totaled $646.8 million. Net losses were $27.2 million.

Arcellx reported collaboration revenue of $39.3 million and a net loss of $7.2 million for the first quarter ended March 31, 2024. The company's cash, cash equivalents, and marketable securities totaled $691.0 million, expected to fund operations into 2027.

Arcellx reported collaboration revenue of $63.1 million for the fourth quarter of 2023 and ended the quarter with $729.2 million in cash, cash equivalents, and marketable securities, extending the cash runway into 2027. Net income for the quarter was $20.5 million.

Arcellx reported collaboration revenue of $15.0 million for Q3 2023, driven by the Kite Pharma agreement. The company's cash, cash equivalents, and marketable securities totaled $482.7 million as of September 30, 2023, expected to fund operations into 2026. Net loss for the quarter was $39.3 million.

Arcellx reported collaboration revenue of $14.3 million, research and development expenses of $28.3 million, general and administrative expenses of $15.5 million, and a net loss of $23.9 million for the second quarter ended June 30, 2023. The FDA lifted the partial clinical hold on the iMMagine-1 Phase 2 Clinical Program.

Arcellx reported collaboration revenue of $17.9 million due to the Kite partnership, and anticipates current funds to support operations through the first half of 2025.

Arcellx reported a successful year with a strategic collaboration with Kite, progress in clinical trials, and scalable manufacturing setup. The company's cash position is $580 million, which will fund operations through BLA filing of CART-ddBCMA planned for the first half of 2025.

Arcellx reported a net loss of $92.9 million for the third quarter ended September 30, 2022. As of September 30, 2022, Arcellx had cash, cash equivalents, and marketable securities of $280.8 million, which is anticipated to fund its operations for at least the next 12 months.

Arcellx reported its Q2 2022 financial results, highlighting the completion of an upsized follow-on offering, presentation of CART-ddBCMA Phase 1 expansion trial data, and preclinical results from CART-ddBCMA published in Molecular Cancer Therapeutics.